Nyxoah SA, a Belgium-based healthtech company developing neuromodulation-based therapeutic solutions for sleep-disordered breathing, has raised €25 million in a private financing round. Completion of the financing round is subject to customary closing conditions and is expected to occur later this month.
ResMed Inc joined as a new shareholder.
Under the lead of Robert Taub, Nyxoah executive chairman, Cochlear Ltd and several historical shareholders completed the €25 million financing round.
The proceeds will enable Nyxoah to further advance in developing long-term clinical evidence on the Genio system, prepare for the investigational device exemption pivotal trial in the United States, and accelerate the ongoing market access and commercialization activities in Europe, Australia, and New Zealand.
Olivier Taelman, CEO of Nyxoah, says, “We have an innovative approach to treating OSA. Having ResMed, the global leader in sleep apnea, support this significant funding round along with our existing shareholders will help Nyxoah to further accelerate its development.”
